GERMANTOWN，Md.，Feb. 22，2017 （GLOBENEWSWIRE）--Neuralstem，Inc.（Nasdaq：CUR），abiopharmaceuticalcompanyfocusedonthedevelopmentofcentralnervoussystemtherapiesbasedonitsneuralstemcelltechnology，todayannouncedthatU.S.PatentNo.9572807wasissuedbytheUnitedStatesPatentandTrademarkOffice（USPTO）forNSI-189，theleadcompoundinNeuralstem‘sneurogenicsmallmoleculeprogramindevelopmentforthetreatmentofmajordepressivedisorder.US9，572，807hasclaimstoprotocolsforusingNSI-189andrelatedcompoundsfortreatmentofmajordepressivedisorder. CounterpartshavebeenfiledinAustralia，Canada，Europe，Japan，SingaporeandSouthKorea. ThesepatentswillexpireinJune2035.
Thenewpatentaddstotheportfolioofover20U.S.and120foreignissuedandpendingpatentsthatareownedorlicensedtoNeuralsteminthefieldofregenerativemedicine. ThisincludesU.S.PatentNo.9，540，611，issuedonJanuary10，2017bytheUSPTO，coveringthetreatmentofneurodegenerativediseasesusingNSI-566，thecompany’sproprietaryneuralstemcelltherapycandidate.
“Weareexcitedtobebringingforwardtherapeuticoptionsthatcouldmakeatremendousdifferenceinthelivesofthosewhosufferfromnervoussystemdisordersandconditions，”saidRichDaly，ChairmanandCEO，Neuralstem. “Wewillcontinuetoaggressivelyestablishabroadportfolioofintellectualpropertytoprotectourresearchanddevelopmentefforts.”
AboutNeuralstem
Neuralstem’spatentedtechnologyenablesthecommercial-scaleproductionofmultipletypesofcentralnervoussystemstemcells，whicharebeingdevelopedaspotentialtherapiesformultiplecentralnervoussystemdiseasesandconditions.
Neuralstem’stechnologyenablesthegenerationofsmallmoleculecompoundsbyscreeninghippocampalstemcelllineswithitsproprietarysystematicchemicalscreeningprocess. ThescreeningprocesshasledtothediscoveryandpatentingofmoleculesthatNeuralstembelievesmaystimulatethebrain’scapacitytogeneratenewneurons，potentiallyreversingpathophysiologiesassociatedwithcertaincentralnervoussystem（CNS）conditions.
ThecompanyhascompletedPhase1aand1btrialsevaluatingNSI-189，anovelneurogenicsmallmoleculeproductcandidate，forthetreatmentofmajordepressivedisorderorMDD，andiscurrentlyconductingaPhase2efficacystudyforMDD.
Neuralstem’sstemcelltherapyproductcandidate，NSI-566，isaspinalcord-derivedneuralstemcellline.NeuralstemiscurrentlyevaluatingNSI-566inthreeindications：stroke，chronicspinalcordinjury（cSCI），andAmyotrophicLateralSclerosis（ALS）.
NeuralstemisconductingaPhase1safetystudyforthetreatmentofparalysisfromchronicmotorstrokeattheBaYiBrainHospitalinBeijing，China. Inaddition，NSI-566isbeingevaluatedinaPhase1safetystudytotreatparalysisduetochronicspinalcordinjuryaswellasaPhase1andPhase2ariskescalation，safetytrialsforALS. Patientsfromallthreeindicationsarecurrentlyinlong-termobservationalfollow-upperiodstocontinuetomonitorsafetyandpossibletherapeuticbenefits.
CautionaryStatementRegardingForwardLookingInformation
Thisnewsreleasecontains“forward-lookingstatements”madepursuanttothe“safeharbor”provisionsofthePrivateSecuritiesLitigationReformActof1995.Suchforward-lookingstatementsrelatetofuture，notpast，eventsandmayoftenbeidentifiedbywordssuchas“expect，”“anticipate，”“intend，”“plan，”“believe，”“seek”or“will.”Forward-lookingstatementsbytheirnatureaddressmattersthatare，todifferentdegrees，uncertain.Specificrisksanduncertaintiesthatcouldcauseouractualresultstodiffermateriallyfromthoseexpressedinourforward-lookingstatementsincluderisksinherentinthedevelopmentandcommercializationofpotentialproducts，uncertaintyofclinicaltrialresultsorregulatoryapprovalsorclearances，needforfuturecapital，dependenceuponcollaboratorsandmaintenanceofourintellectualpropertyrights.Actualresultsmaydiffermateriallyfromtheresultsanticipatedintheseforward-lookingstatements.AdditionalinformationonpotentialfactorsthatcouldaffectourresultsandotherrisksanduncertaintiesaredetailedfromtimetotimeinNeuralstem’speriodicreports，includingtheAnnualReportonForm10-KfortheyearendedDecember31，2015，andForm10-QfortheninemonthsendedSeptember30，2016，filedwiththeSecuritiesandExchangeCommission（SEC），andinotherreportsfiledwiththeSEC.Wedonotassumeanyobligationtoupdateanyforward-lookingstatements.
CONTACT：DanielleSpangler
nvestorRelations
euralstem，Inc
01.366.1481
LoriRosen
ublicRelations
DRCommunications
